2025 Silent Capital Report now available. Where family offices and LPs are actually deploying. [Download for free →]
About usSign in
Status
ACTIVE
Global HQ
London, United Kingdom
Countries of investment
  • United Kingdom
  • United States
  • France
  • Netherlands
  • Belgium
Investment stages
  • Seed
  • Series A
  • Series B
  • Series C
  • Growth
Industries
  • Life Sciences
  • Biotechnology
  • Pharma
  • MedTech
  • Medical Devices
  • Diagnostics
  • Digital Health
About
Advent Life Sciences is a London venture firm spun out of Advent Venture Partners and led by co-founders Shahzad Malik and Raj Parekh, with offices in the UK, France and the US. Its portfolio includes uniQure, Proximie, Cyted Health and F2G, and past exits include Algeta and Avila Therapeutics. In September 2026 the British Business Bank committed £60M to Advent Life Sciences Fund IV and £75M to the Advent Life Sciences Growth Fund.
Min check size
$5M
Max check size
$20M
Fund size
NPS

Investment Thesis

Advent Life Sciences founds and invests in life sciences companies developing new medicines, medical technologies, vaccines and enabling platforms across the UK, Europe and the US, backing first-in-class or best-in-class approaches. It covers the financing path from early-stage company creation through mid and late-stage clinical development, through its flagship fund and a dedicated growth fund.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

General Partner Shahzad Malik joined Advent in 1999 with a background in clinical medicine and international finance. He has worked with more than 25 portfolio companies, including Algeta, Respivert, Biocartis and Axonics. General Partner Raj Parekh joined in 2005 after more than 20 years in biomedical research, including senior roles at Oxford GlycoSciences, and is chairman of Galapagos. The partnership also includes General Partners Kaasim Mahmood, Dominic Schmidt and Satish Jindal. Its portfolio has produced IPOs including uniQure, Centessa and Aura Biosciences.

Advent Life Sciences Contacts Information

Primary contact

Secondary contact

Team

Shahzad Malik - General Partner

Raj Parekh - General Partner

Kaasim Mahmood - General Partner

Dominic Schmidt - General Partner

Satish Jindal - General Partner

Fraser Murray - Head of Scientific Evaluation

Don Drakeman - Venture Partner

Portfolio

uniQure

Proximie

Cyted Health

F2G

Beacon Therapeutics

Glycomine

Aura Biosciences

Centessa

Algeta

Biocartis

Fund number
Year Founded
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp